Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ultromics logo — Ultromics is transforming the detection of heart failure usi...

Ultromics

Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.

Founded 2017 United Kingdom Oxford, United Kingdom 85 employees Series C Total: $93.70M AI, Computer Vision +1

General Information

Company Name Ultromics
Founded Year 2017
Location United Kingdom Oxford, United Kingdom +1
Employees 85
Industries AI, Computer Vision, Health Care
Funding Stage Series C
Social

Get notified when Ultromics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Sep 24, 2026

Ultromics is participating in the event Advances in the Diagnosis and Treatment of Amyloidosis in 2026 at NYU Langone Health.

Growth Metrics Sep 10, 2026

Ultromics' EchoGo platform has been trained on more than 430,000 echocardiograms.

New Partnership Sep 10, 2026

Ultromics' EchoGo platform has been validated in studies with the Mayo Clinic.

Award Received Sep 10, 2026

Ultromics was nominated and recognized on the Tech Funding News list of UK healthtech companies worth watching.

Regulatory Approval Sep 10, 2026

Ultromics highlights its FDA-cleared technology, emphasizing its foundation for real-world adoption in clinical practice.

Get alerts when Ultromics shows new signals

About Ultromics

Ultromics, founded in 2017, is at the forefront of revolutionizing heart failure detection through its innovative use of artificial intelligence in echocardiography. Headquartered in the United Kingdom, the company stands out within the AI, Computer Vision, and Health Care industries.

Their flagship product, EchoGo®, leverages one of the world's largest heart disease datasets to provide precision diagnostics for heart failure, particularly tackling complex conditions such as HFpEF. The platform's ability to deliver precise and efficient assessments is bolstered by strategic collaborations with prestigious partners such as the Mayo Clinic, Johnson & Johnson, and Pfizer.

Ultromics recently secured a €48.00M Series C investment on 31 July 2025 from a distinguished group of investors, including Blue Venture Fund, GV, Lightrock, Allegis Capital, and others, reflecting strong market confidence in its disruptive potential.

Taxonomy: artificial_intelligence, echocardiography, heart_failure_detection, precision_medicine, cardiac_ultrasound, HFpEF, clinical_diagnostics, healthcare_technology, medical_imaging, cardiology, partnership_with_mayo_clinic, partnership_with_johnson_and_johnson, partnership_with_pfizer, early_intervention, heart_disease_dataset

Services & Products

AI-powered HFpEF detection
AI-powered Cardiac Amyloidosis detection
EchoGo® Integration and analytics
Automated diagnostic reporting

Target Customers

Healthcare Institutions Cardiologists Clinical Decision Support Teams Hospitals and Clinics

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 9
Investor Investor Investor Investor Investor
•••• •••• 		31 Jul 2025
Series B •••••• 4
Investor Investor Investor
•••• •••• 		16 Aug 2021
Series A •••••• 1
Investor
15 Jun 2020
Venture Round •••••• 1
Investor
01 Nov 2019
Series A •••••• 4
Investor
•••• •••• 		22 May 2018

View All 6 Funding Rounds

Latest News

View All
Britain’s cardiology diagnostics solution Ultromics raises €48 million to detect elusive forms of he... — Eu-startups
Britain’s cardiology diagnostics solution Ultromics raises €48 million to detect elusive forms of heart failure
Eu-startups Jul 31, 2025
Ultromics raises $55M Series C to scale AI-driven heart failure detection — Tech
Ultromics raises $55M Series C to scale AI-driven heart failure detection
Tech Jul 31, 2025
Paris-based Lifeaz raises €13 million to democratise defibrillator access and save 1000 lives within... — Eu-startups
Paris-based Lifeaz raises €13 million to democratise defibrillator access and save 1000 lives within five years
Eu-startups Feb 12, 2026
Advancing cardiovascular health – SignaCor Therapeutics lands €288k investment as pat of €1.1 millio... — Eu-startups
Advancing cardiovascular health – SignaCor Therapeutics lands €288k investment as pat of €1.1 million Seed round
Eu-startups Mar 09, 2026

Ultromics Alternatives & Competitors

View All Alternatives
Ultromics vs
Fallouh Healthcare
Fallouh Healthcare United Kingdom

Fallouh Healthcare, is a Medical Device start-up company developing a medical device used for monito...

2 employees
Ultromics vs
CorInnova, Inc.
CorInnova, Inc. United States

Developing a non-blood contacting biventricular cardiac assist device for patients with heart failur...

Grant
15 employees
Health Care, Health and Wellness
Compare Ultromics vs CorInnova, Inc.
Ultromics vs
Cardiovascular Institute of Central Florida, LLC
Cardiovascular Institute of Central Florida, LLC

Experienced, Board-Certified Cardiologists in Ocala and The Villages.

47 employees
Health Care
Also compare with: Ultromics vs Vital Metrix Vital Metrix Ultromics vs Biosense Webster Biosense Webster View all alternatives

FAQ About Ultromics

Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.
Ultromics was founded in 2017.
Ultromics is headquartered in Oxford, United Kingdom.
Ultromics operates in the following industries: AI, Computer Vision, Health Care.
Ultromics has approximately 85 employees.
Ultromics has completed 6 funding rounds, raising a total of $93.70M. The latest funding stage is Series C.
Ultromics offers: AI-powered HFpEF detection, AI-powered Cardiac Amyloidosis detection, EchoGo® Integration and analytics, Automated diagnostic reporting.
Top alternatives and competitors to Ultromics include Fallouh Healthcare, CorInnova, Inc., Cardiovascular Institute of Central Florida, LLC, Vital Metrix, Biosense Webster. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ultromics and Fallouh Healthcare are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ultromics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes